Wang Qian, Wang Ke, Zhao Xianxian
Department of Cardiology, Changhai Hospital, Naval Medical University, No.168 Changhai Road, Shanghai 200433, China.
Regen Med. 2021 Jan;16(1):9-17. doi: 10.2217/rme-2020-0047. Epub 2021 Feb 9.
Mesenchymal stem cell (MSC) transplantation is a promising therapeutic approach for acute myocardial infarction (AMI), however, research to date has demonstrated unsatisfactory results. An AMI mouse model was established via left coronary artery ligation. AMI mice were treated with MSCs, anti-CCR2 or MSCs + anti-CCR2 and the effects of each treatment group were compared. Macrophage infiltration was analyzed by immunofluorescence staining and flow cytometry. Implantation of MSCs + anti-CCR2 yielded a greater improvement in cardiac function and significantly reduced macrophage accumulation in the infarct site of AMI mice compared with the injection of MSCs or anti-CCR2 alone. Moreover, reduced macrophage infiltration was accompanied by reduced pro-inflammatory cytokine secretion in the injury sites and the low inflammatory response favored tissue regeneration. Treatment with MSCs and anti-CCR2 in combination may be a promising therapeutic strategy for AMI.
间充质干细胞（MSC）移植是治疗急性心肌梗死（AMI）的一种很有前景的治疗方法，然而，迄今为止的研究结果并不理想。通过左冠状动脉结扎建立AMI小鼠模型。用MSC、抗CCR2或MSC +抗CCR2治疗AMI小鼠，并比较各治疗组的效果。通过免疫荧光染色和流式细胞术分析巨噬细胞浸润情况。与单独注射MSC或抗CCR2相比，植入MSC +抗CCR2能使AMI小鼠的心脏功能有更大改善，并显著减少梗死部位的巨噬细胞聚集。此外，巨噬细胞浸润减少伴随着损伤部位促炎细胞因子分泌减少，且低炎症反应有利于组织再生。联合使用MSC和抗CCR2治疗可能是一种有前景的AMI治疗策略。
